AbbVie Inc. Return on Tangible Assets

Return on Tangible Assets of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Return on Tangible Assets growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Return on Tangible Assets for 2019 was 0.0% (a -100.0% decrease from previous year)
  • Annual Return on Tangible Assets for 2018 was 219.66% (a 205.55% increase from previous year)
  • Annual Return on Tangible Assets for 2017 was 71.89% (a 8.81% increase from previous year)
  • Twelve month Return on Tangible Assets ending December 30, 2019 was 0.0% (a -100.0% decrease compared to previous quarter)
  • Twelve month trailing Return on Tangible Assets decreased by -100.0% year-over-year
Trailing Return on Tangible Assets for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
0.0% 58.47% 396.72% 159.1%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Return on Tangible Assets of AbbVie Inc.

Most recent Return on Tangible Assetsof ABBV including historical data for past 10 years.

Interactive Chart of Return on Tangible Assets of AbbVie Inc.

AbbVie Inc. Return on Tangible Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 0.0%
2018 219.66%
2017 71.89%
2016 66.07%
2015 64.42%
2014 24.73%
2013 31.11%
2012 48.73%
2011 95.33%
2010 61.31%
2009 0.0%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.